Compare Illumina, Inc. (ILMN) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Oklo Inc — how do they compare? Illumina, Inc. trades at $267.69 (market cap $39.95B), while Oklo Inc trades at $34.26 (market cap $6.43B). The key difference: Illumina, Inc. is far larger — about 6.2× Oklo Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Oklo Inc for 31 Days on average.
| ILMN | OKLO | |
|---|---|---|
Market Cap | $39.95B | $6.43B |
Volume | 3,169,503 | 16,238,368 |
Sector | Health | Utilities |
52-Week High | $293.69 | $174.14 |
52-Week Low | $91.00 | $34.57 |
Typical Hold Time | 83 Days | 31 Days |
Enterprise Value | $41.31B | $3.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
OKLO trades at $36.82, down 4.49% with bearish technical signals. The company shows no revenue in 2025 and negative net income of -$105.66M, with profitability metrics deeply negative. Recent earnings have missed expectations in two of the last three quarters. However, analyst sentiment remains strong with 71% buy ratings and a $78.63 consensus price target, reflecting optimism about the nuclear energy opportunity.
The outlook balances high growth potential in the nuclear sector against significant execution risks. While the $10 trillion nuclear opportunity and partnerships with hyperscalers provide upside, OKLO faces challenges including negative cash flow from operations, substantial dilution from recent stock sales, and intense competition in the small modular reactor market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
